US stock market anomaly | Sanofi throws $9.1 billion to acquire Blueprint Medicines (BPMC.US), surging nearly 26%

According to the Securities Times Finance APP, on Monday, Blueprint Medicines (BPMC.US) opened with a significant increase of nearly 26%, reaching a historic high of $127.46. In terms of news, French pharmaceutical giant Sanofi (SNY.US) will acquire the American biopharmaceutical company Blueprint Medicines for $9.1 billion in stock value, significantly enhancing its treatment pipeline in the rare immune disease field. According to a joint statement released by both parties on Monday, Sanofi will acquire Blueprint at a cash price of $129 per share, a 27% premium over Blueprint's closing price last Friday.